Thomas L. Petty Aspen Lung Conference - 55th Annual Meeting Aspen, Colorado, USA, 6–9 June, 2012

Topics

  • 1.1 L-Citrulline transport and chronic hypoxia-induced pulmonary hypertension in newborn piglets
  • 1.2 Umbilical cord blood angiogenic progenitor cells are decreased in moderate and severe bronchopulmonary dysplasia
  • 1.3 Subcellular mechanisms in IPAH-dysfunctions of the Golgi apparatus/endoplasmic reticulum/mitochondrial axis
  • 1.4 Endostatin (Col18a1) as a novel determinant of disease susceptibility and severity in pulmonary hypertension
  • 1.5 Computed tomographic assessment of pulmonary vascular remodeling in smokers
  • 1.6 Potential biomarkers in pulmonary arterial hypertension associated with limited scleroderma
  • 1.7 Pulmonary arterial hypertension in a non-human primate model of HIV
  • 1.8 Efficacy and safety of imatinib in the treatment of pulmonary arterial hypertension
  • 1.9 MTORC2 regulates vascular smooth muscle cell metabolism in pulmonary arterial hypertension
  • 1.10 Schistosomiasis-induced pulmonary vascular disease is IL4/IL13 and TGF-β dependent
  • 1.11 BMPR2 alternative splicing and PAH: A molecular explanation for gender discrepancy?
  • 1.12 Thrombospondin-1 inhibits proliferation of pulmonary vascular smooth muscle and endothelial cells: A mechanism for loss-of-function thrombospondin-1 mutations as modifiers in familial PH
  • 1.13 In vivo circulating fibrocytes ablation in the setting of pulmonary hypertension murine model
  • 1.14 Therapeutic targeting of microRNAs in pulmonary hypertension
  • 1.15 FK506-identified in a high throughput screen to increase BMRP2 signaling-reverses pulmonary hypertension by rescuing endothelial dysfunction
  • 1.16 Proteomic signature of the human right ventricle in heart failure
  • 1.17 Nitrate is cardioprotective in an obese and pulmonary hypertensive rat model
  • 1.18 Changes in right ventricular function in a mouse model of severe pulmonary hypertension
  • 1.19 Loss of tolerance associated with bronchus associated lymphoid tissue expansion in experimental pulmonary hypertension
  • 1.20 Impaired pulmonary angiogenesis in idiopathic pulmonary arterial hypertension is linked to abnormal pericyte function and reduced endothelial-pericyte interactions
  • 1.21 Macrophage migration inhibitory factor: A mediator of hypoxia-induced pulmonary hypertension
  • 1.22 Preservation of capillary network of the right ventricle in severe experimental pulmonary hypertension
  • 1.23 Assessment of pulmonary vascular remodeling in pulmonary arterial hypertension in vivo using 18F-FDG PET imaging
  • 1.24 Extracellular superoxide dismutase modulates NALP3 inflammation in chronic hypoxic mouse models
  • 1.25 Hyaluronan (HA) mediates the effects of nitric oxide (NO) on cell proliferation in pulmonary hypertension
  • 1.26 NF-kB dimer activity in pul monary hypertension induced by hypoxia
  • 1.27 Serotonylated fibronectin in pulmonary hypertension
  • 1.28 Characterization of the vascular response to acute inflammatory injury in the lung
  • 1.29 Mitochondrial dysfunction underlies susceptibility of rats with low intrinsic aerobic capacity to hypoxia-induced pulmonary hypertension
  • 1.30 Enhanced expression of cabeolin01 in smooth muscle cells may determine irreversibility of pulmonary hypertension
  • 1.31 A combination of biomarkers and hemodynamics predicts outcomes in children with pulmonary arterial hypertension
  • 1.32 Peripheral chemoreceptor responsiveness and hypoxic pulmonary vasoconstriction in humans
  • 1.33 Gene deletion of JNK1/2 blunts vascular remodeling in hypoxia-induced pulmonary hypertension 
  • 1.34 Microparticles from mice with monocrotaline-induced pulmonary hypertension induce right ventricular hypertrophy and pulmonary vascular remodeling in healthy mice
  • 1.35 IL-13, IL-17 and B cell response in pulmonary hypertension
  • 1.36 Exercise training in pulmonary arterial hypertension associated with connective tissue diseases
  • 1.37 Inhibition of Gbg signaling decreases pulmonary artery pressure and regresses vascular remodeling in experimental pulmonary hypertension
  • 1.38 Alterations of pulmonary artery metabolism in severe pulmonary arterial hypertension
  • 1.39 Mitofusion-2 plays a critical role in mitochondrial dysfunction in pulmonary hypertension and is a potential therapeutic target
  • 1.40 Macrophage migration inhibitory factor deficiency promotes increased right ventricular endostatin expression and reduced capillary density in a model of chronic hypoxic pulmonary hypertension
  • 1.41 Premature differentiation of vascular smooth muscle cells in human congenital diaphragm hernia
  • 1.42 The development of pulmonary hypertension after first episode of acute pulmonary embolism and related risk factors
  • 1.43 Activation of NRF2 attenuates hypoxia-induced cardiopulmonary alterations in mice
  • 1.44 Pulmonary artery vortex parameters for the prediction of pulmonary vascular hemodynamics
  • 1.45 Endothelial Krüppel-like factor 4 modulates pulmonary arterial hypertension
  • 1.46 Establishing of a pure endothelial cell culture from differentiating murine embryonic stem cells
  • 1.47 Pulmonary vasculature develops from WNT2+ cardiac mesoderm coordinated by endoderm-secreted SHH
  • 1.48 A female model of severe neointimal pulmonary hypertension: Evidence for increased susceptibility in a female rat following pneumonectomy and monocrotaline
  • 1.49 Stem cell-like cells in angioproliferative lesions in the SU5416/chronic hypoxia model of angioproliferative PAH
  • 1.50 Acute vasodilator testing with sildenafil versus nitric oxide in patients with pulmonary arterial hypertension
  • 1.51 Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy
  • 1.52 Right ventricular dysfunction due to pulmonary arterial hypertension is characterized by metabolic gene remodeling and abnormal mitochondrial function and maintenance
  • 1.53 Urokinase plasminogen activator receptor expression in pulmonary venous hypertension due to left heart failure
  • 1.54 Exposure to cigarette smoke causes dysfunction
  • 1.55 Blockade of hypoxia-induced CA2+ release by acetazolamide (ACZ) in pulmonary arterial smooth muscle cells
  • 1.56 Haplotype association mapping in 33 inbred mouse strains identifies genetic regions contributing to chronic hypoxia-induced pulmonary hypertension
  • 1.57 Therapeutic potential of histone deacetylation inhibitors in pulmonary arterial hypertension
  • 1.58 Sustained endothelial injury to maintain hyperproliferation and apoptosis-resistance in pulmonary arterial hypertension
  • 1.59 Determining treatment efficacy in pulmonary arterial hypertension
  • 1.60 Defective eNOS phosphorylation in idiopathic pulmonary arterial hypertension
  • 1.61 CD39/CD73-mediated immune responses in pulmonary arterial hypertension
  • 1.62 Estrogens induce right ventricle-pulmonary vasculature uncoupling in female rat model of accelerated angioproliferative pulmonary hypertension
  • 1.63 Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMα)-induced pulmonary endothelial cell activation is critical for the later development of pulmonary hypertension and right heart dysfunction
  • 1.64 Speckle tracking echocardiograph as a screening method for pulmonary hypertension in severe COPD
  • 1.65 The TLR4/MyD88 signaling pathway is required for complement-dependent platelet activation chronic hypoxia-induced pulmonary hypertension
  • 1.66 Protective effects of 17-beta estradiol (E2) in hypoxic pulmonary hypertension are mediated by estrogen receptors alpha and beta
  • 1.67 Hemodynamic and genetic analysis in children with idiopathic/heritable and congenital heart disease associated pulmonary arterial hypertension
  • 1.68 β-2 adrenergic receptor polymorphism and gene expression are associated with risk of development of and disease severity in scleroderma associated pulmonary arterial hypertension
  • 1.69 Pulmonary arterial hypertension induces gene expression changes in the right ventricle in advance of right ventricular failure that are more severe in female rats
  • 1.70 Integration of genome-wide microRNA and mRNA expression profiles in pulmonary arterial hypertension and pulmonary hypertension associated with idiopathic pulmonary fibrosis
  • 1.71 WNT-signaling pathway in right ventricular remodeling
  • 1.72 Sex and hemodynamics in pulmonary arterial hypertension
  • 1.73 Distribution of radial distensibility in canine pulmonary vasculature

Published in:

Pulmonary Circulation Vol 3: No 1 cover image

March 2013

Pulmonary Circulation Vol 3: No 1

View this journal

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg